3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
2
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
14
Gastrointestinal
3
Head & Neck
2
Gynecologic
2
Genitourinary
2
Dermatologic
2
NET
1
Endocrine
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
6391
Neoplasms
408
Ovarian Neoplasms
308
Triple Negative Breast Neoplasms
286
Prostatic Neoplasms
280
Lung Neoplasms
271
Colorectal Neoplasms
255
Neoplasm Metastasis
253
Carcinoma, Non-Small-Cell Lung
221
Breast Neoplasms, Male
201
Colonic Neoplasms
168
Motor Activity
166
Pancreatic Neoplasms
164
Melanoma
157
Carcinoma, Intraductal, Noninfiltrating
139
Stomach Neoplasms
128
Uterine Cervical Neoplasms
127
Head and Neck Neoplasms
124
Fatigue
104
Breast Carcinoma In Situ
103
Carcinoma, Ovarian Epithelial
98
Endometrial Neoplasms
96
Lymphedema
95
Carcinoma, Renal Cell
94
Urinary Bladder Neoplasms
93
Pain
90
Sarcoma
89
Small Cell Lung Carcinoma
85
Lymphoma
83
Esophageal Neoplasms
81
Interventions
exemestane
1
entinostat
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Respiratory Tract Diseases
×
Breast
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled